Committee(s):	Dated:
Health and Wellbeing Board – For decision	26 November 2021
Subject: Update on the City and Hackney	Public
Pharmaceutical Needs Assessments 2022	
Which outcomes in the City Corporation's Corporate	2,3,4
Plan does this proposal aim to impact directly?	
Does this proposal require extra revenue and/or	N
capital spending?	
If so, how much?	
What is the source of Funding?	
Has this Funding Source been agreed with the	
Chamberlain's Department?	
Report of: Sandra Husbands, Director of Public Health	For Decision
Report author: Andrew Trathen, Consultant in Public	
Health	

#### 1. SUMMARY

- 1.1. Since 1 April 2013, every Health and Wellbeing Board (HWB) in England has had a statutory responsibility to publish and keep up to date a statement of the needs for pharmaceutical services for the population in its area, referred to as a 'Pharmaceutical Needs Assessment' (PNA).
- 1.2. Data contained within the assessment will be used to plan pharmaceutical services in the borough to best meet local health needs.
- 1.3. The production of the 2022 PNAs for both the City of London and London Borough of Hackney have commenced.

### 2. RECOMMENDATIONS

- 2.1. To note that the process to produce a revised PNA by 1<sup>st</sup> October 2022 has commenced.
- 2.2. To receive the Terms of Reference (ToR) for the City of London and London Borough of Hackney PNA Steering Group.
- 2.3. To receive an update on progress and the project plan timelines from the City of London and London Borough of Hackney PNA Steering Group on the production of the 2022 PNAs.
- 2.4. To formally delegate the sign-off of the draft and final PNAs to the Steering Group.

### **Main Report**

#### 3. BACKGROUND

- 3.1. The PNA is a report of the present needs for pharmaceutical services. It is used to identify any gaps in current services or improvements that could be made in future pharmaceutical service provision. To prepare the report, data is gathered from pharmacy contractors, pharmacy users and other residents and from a range of sources (commissioners, planners and others). The report also includes a range of maps that are produced from data collected as part of the PNA process.
- 3.2. The PNA Steering Group had its first meeting on 7<sup>th</sup> October 2021. At this meeting, a Terms of Reference (Appendix A) for the group and Project Plan (Appendix B) for the PNA were agreed.
- 3.3. The steering group are presently collecting information from service providers, commissioners, and London Borough of Hackney & City of London public on current pharmaceutical service provision.
- 3.4. An external expert resource, Soar Beyond Ltd, has been commissioned to support the preparation of the draft PNA 2022 report. Soar Beyond have extensive expertise in producing PNAs, having produced 8 in 2015 and 12 in 2018.

### 4. KEY CONSIDERATIONS AND SUSTAINABILITY

- 4.1. 'Pharmaceutical Needs Assessments' or 'PNAs' are a special assessment of pharmaceutical services provision in an area. The PNA includes information on current pharmaceutical service provision, information on health and other needs, and an assessment on whether current provision meets current or future needs of the area. It is a mandatory exercise. The Health and Social Care Act 2012 transferred responsibility for developing and updating PNAs to Health and Wellbeing Boards (HWBs). The NHS (Pharmaceutical Services and Local Pharmaceutical Services) Regulations 2013 set out the legislative basis for developing and updating PNAs.
- 4.2. Surveys will be undertaken with the public, commissioners, and community pharmacy contractors in the respective Local Authorities, to seek opinion on current pharmaceutical services provided in the City of London and London Borough of Hackney. These surveys will be carried out and completed over the coming month.

- 4.3. The draft PNA 2022 is currently being provided by the external consultants, Soar Beyond Ltd, commissioned by City of London and London Borough of Hackney to support the production of the PNA. The draft assessment will be considered by the Steering Group at a meeting week commencing 4<sup>th</sup> April 2022.
- 4.4. Upon approval of a draft PNA by the Steering Group, the assessment will be made available for a 60-day consultation between 9<sup>th</sup> May 2022 to 10<sup>th</sup> July 2022.
- 4.5. The results of consultation will be considered by the Steering Group at its meeting week commencing 25<sup>th</sup> July 2022, and a final PNA produced for publication
- 4.6. The final PNA must be published no later than 1st October 2022.

#### 5. PROPOSAL

5.1. It is proposed that the approval to publish the final PNA is delegated to the Steering Group and the final assessment provided for information to the Health and Wellbeing Board in October 2022.

#### 6. FINANCIAL CONSIDERATIONS

6.1. Funding for the production of the Pharmaceutical Needs Assessment for 2022 has already been allocated from the Public Health Grant and apportioned across City and Hackney based upon the number of community pharmacies within each Local Authority.

#### 7. LEGAL CONSIDERATIONS

7.1. None

#### 8. RESOURCE IMPLICATIONS

8.1. None

#### 9. RISK IMPLICATIONS

9.1. None

#### 10. CLIMATE IMPLICATIONS

10.1. None

## 11. SECURITY IMPLICATIONS

11.1. None

## 12. EQUALITY IMPACT ASSESSMENT

12.1. An Equality Impact Assessment will be produced and maintained by the provider, Soar Beyond Ltd.

# 13. Appendices

# Appendix A

Steering Group Terms of Reference

## **Appendix B**

Timeline/Project Plan

Andrew Trathen
Consultant in Public Health
Andrew.trathen@hackney.gov.uk